ライフサイエンスコーパス: schistosomiasis

1 is), ulcer care (leprosy), or renal support (schistosomiasis).

2 ble for the pathogenesis and transmission of schistosomiasis.

3 ta from the national surveillance system for schistosomiasis.

4 ex life cycle of the parasites causing human schistosomiasis.

5 nt a new risk factor for PAH associated with schistosomiasis.

6 ffective vaccines and chemotherapies against schistosomiasis.

7 redators of the snail intermediate hosts for schistosomiasis.

8 treating the bladder sequelae of urogenital schistosomiasis.

9 at macrophages prevent death from urogenital schistosomiasis.

10 he repurposing or discovery of drugs against schistosomiasis.

11 for development of new strategies to control schistosomiasis.

12 contribution to controlling, or eliminating, schistosomiasis.

13 y the pulmonary vascular response to chronic schistosomiasis.

14 cts for the development of a vaccine against schistosomiasis.

15 to the increased regulatory milieu found in schistosomiasis.

16 infections, including the helminthic disease schistosomiasis.

17 ssion model might overestimate human risk of schistosomiasis.

18 Bregs) on T-cell cytokines in vitro in human schistosomiasis.

19 ium worms, the etiologic agent of urogenital schistosomiasis.

20 may be involved in the pathogenesis of human schistosomiasis.

21 at MBL is also associated with protection in schistosomiasis.

22 etwork of host-parasite relationships during schistosomiasis.

23 2 serum levels as protective factors against schistosomiasis.

24 These responses are tightly regulated during schistosomiasis.

25 y and MBL2 polymorphisms are associated with schistosomiasis.

26 the hepatic B cell infiltrate during chronic schistosomiasis.

27 subjects (10%) had severe manifestations of schistosomiasis.

28 l-fetal health in pregnancies complicated by schistosomiasis.

29 ficolin-2 serum levels and susceptibility to schistosomiasis.

30 ssociations among hepatomegaly, malaria, and schistosomiasis.

31 1 for -4A>G) were observed to shield against schistosomiasis.

32 ll as an obligatory contribution of liver in schistosomiasis.

33 progression of hepatic fibrosis in mice with schistosomiasis.

34 's 200 million to 400 million cases of human schistosomiasis.

35 agas disease, leishmaniasis, filariasis, and schistosomiasis.

36 mediated B cell activation in the context of schistosomiasis.

37 el of IBD and on granuloma T cells in murine schistosomiasis.

38 te, no vaccine is available to prevent human schistosomiasis.

39 , neutrophilia, and endotoxemia during acute schistosomiasis.

40 Sm-p80 as a promising vaccine candidate for schistosomiasis.

41 the development of immunopathology in murine schistosomiasis.

42 for the decline in Th2 responses in chronic schistosomiasis.

43 ganization for lead compound development for schistosomiasis.

44 ections such as Lyme disease, amebiasis, and schistosomiasis.

45 al evaluation of paramyosin as a vaccine for schistosomiasis.

46 s controls the outcome of immunopathology in schistosomiasis.

47 terleukin-4 (P = 0.001) than animals without schistosomiasis.

48 y within families in rural areas endemic for schistosomiasis.

49 There is currently no vaccine against schistosomiasis.

50 aneous leishmaniasis but beneficial in acute schistosomiasis.

51 ontribute to developing new vaccines against schistosomiasis.

52 er from severe morbidity as a consequence of schistosomiasis.

53 d at reducing snail-mediated transmission of schistosomiasis.

54 confirmed non-TB tropical diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cut

55 iciency virus (HIV)/AIDS (7%), malaria (7%), schistosomiasis (6%), and strongyloidiasis (5%); 5% were

56 Schistosomiasis, a chronic helminth infection, elicits d

57 Schistosoma mansoni is a causative agent of schistosomiasis, a disease that constitutes a major heal

58 mansoni is one of the etiological agents of schistosomiasis, a key neglected tropical disease respon

59 ke Schistosoma haematobium causes urogenital schistosomiasis, a neglected tropical disease (NTD) that

60 changes are occurring in the epidemiology of schistosomiasis, a neglected tropical disease caused by

61 a haematobium, is the most prevalent form of schistosomiasis affecting humans, and can result in seve

62 Schistosomiasis affects approximately 40 million women o

63 Schistosomiasis affects more than 200 million individual

64 Schistosomiasis affects nearly 40 million women of repro

65 Regional diagnoses included schistosomiasis (Africa) and Chagas disease (Americas).

66 We describe an outbreak of acute schistosomiasis after a brief exposure (mean, 22 +/- 9.5

67 deworming for soil-transmitted helminths or schistosomiasis (alone or in combination with other inte

68 e is the trematode Schistosoma, which causes schistosomiasis, an infectious disease, whose pathology

69 raziquantel (40 mg/kg per treatment) against schistosomiasis and albendazole (400 mg per treatment) a

70 rge-scale administration of praziquantel for schistosomiasis and albendazole for soil-transmitted hel

71 tidae, the parasites responsible for causing schistosomiasis and cercarial dermatitis.

72 s and infertility associated with urogenital schistosomiasis and discuss the basic hormonal mechanism

73 loped a transmission model of female genital schistosomiasis and HIV infections that we fit to epidem

74 conomically attractive strategy for reducing schistosomiasis and HIV transmission in sub-Saharan Afri

75 Naturally occurring human immunity to both schistosomiasis and hookworm infection has been associat

76 ew insights into improved treatment for both schistosomiasis and other granulofibrotic diseases.

77 potential mechanistic link between maternal schistosomiasis and poor birth outcomes will contribute

78 l preventive chemotherapy programmes against schistosomiasis and soil-transmitted helminthiasis are l

79 ntegrated, community-wide MDA programmes for schistosomiasis and soil-transmitted helminthiasis can b

80 hich would have received annual MDA for both schistosomiasis and soil-transmitted helminthiasis under

81 anthelmintic drugs for morbidity control of schistosomiasis and soil-transmitted helminthiasis, whic

82 ed MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted helminthiasis.

83 to address the substantial disease burden of schistosomiasis and soil-transmitted helminthiasis.

84 rapy and complementary interventions against schistosomiasis and soil-transmitted helminthiasis.

85 d preventive chemotherapy programmes against schistosomiasis and soil-transmitted helminthiasis.

86 ies is the mainstay of morbidity control for schistosomiasis and soil-transmitted helminths, yet the

87 between the maternal immune responses during schistosomiasis and the progeny's predisposition to alle

88 community-based intervention for preventing schistosomiasis and, consequently, HIV infections in rur

89 er for assessing risk of hepatic fibrosis in schistosomiasis and, potentially, other infectious and n

90 Malaria, schistosomiasis, and chronic kidney disease-related anem

91 world, is the causative agent of urogenital schistosomiasis, and is associated with a high incidence

92 asis, malaria, leishmaniasis, toxoplasmosis, schistosomiasis, and paracoccidioidomycosis, in which ho

93 No vaccine is available to prevent schistosomiasis, and treatment relies predominantly on t

94 hepatomegaly in areas where both malaria and schistosomiasis are endemic is poor regulation of an inf

95 Malaria and schistosomiasis are the world's two most important paras

96 The worm's eggs, which cause the symptoms of schistosomiasis, are generally used to diagnose the dise

97 granulomas occur, such as leishmaniasis and schistosomiasis, Arg1 plays additional roles such as T-c

98 orld Health Organization's goal to eliminate schistosomiasis as a global health problem by 2025, ther

99 rasite vaccine development using malaria and schistosomiasis as examples.

100 Lung tissue from patients with schistosomiasis-associated and connective tissue disease

101 Lung tissue from patients with schistosomiasis-associated and connective tissue disease

102 Schistosomiasis-associated PAH shares altered vascular T

103 novel therapeutic approach for patients with schistosomiasis-associated PAH.

104 The etiology of schistosomiasis-associated pulmonary arterial hypertensi

105 Lungs of patients with schistosomiasis-associated pulmonary arterial hypertensi

106 ess whether treatment of pregnant women with schistosomiasis at 12-16 weeks gestation leads to improv

107 hods and Twenty-six returning travelers with schistosomiasis (based on positive results of serologic

108 HIV/AIDS and schistosomiasis both cause a substantial disease burden

109 ry findings resembled those of classic acute schistosomiasis, but the detected eggs were morphologica

110 drug administration (MDA) for the control of schistosomiasis, but they have not been studied during t

111 ssue injury caused by worm eggs during acute schistosomiasis by suppressing IL-12/IL-23p40 production

112 k, showing how easily and rapidly urogenital schistosomiasis can be introduced and spread into novel

113 y can modulate infant immune development and schistosomiasis can occur from early infancy, such that

114 ium, the two species responsible for >99% of schistosomiasis cases worldwide.

115 Co-infections with schistosomiasis caused more severe liver disease than in

116 Urogenital schistosomiasis, caused by Schistosoma haematobium, is t

117 Urogenital schistosomiasis, caused by the parasitic trematode Schis

118 Our data indicate that experimental schistosomiasis causes PH and potentially relies on up-r

119 Malaria and schistosomiasis coinfections are common, and chronic sch

120 ed to be a risk factor for susceptibility to schistosomiasis compared with controls, and the haplotyp

121 Soil-transmitted helminthiasis and schistosomiasis, considered among the neglected tropical

122 praziquantel (PZQ) is the strategy for human schistosomiasis control aiming to prevent morbidity in l

123 ly endemic, and impact on the feasibility of schistosomiasis control and elimination goals.

124 ts could help develop specific strategies of schistosomiasis control and elimination tailored to the

125 ave important public health implications for schistosomiasis control and programs targeting other neg

126 We tested schistosomiasis control by reintroduced river prawns in

127 The next generation of schistosomiasis control can be optimized using new monit

128 Two groups of baboons (n = 8 each) and a schistosomiasis control group (n = 3) were infected with

129 MDA) with praziquantel is the cornerstone of schistosomiasis control in sub-Saharan Africa.

130 vels and will guide the spatial targeting of schistosomiasis control interventions.

131 Despite great progress on schistosomiasis control over the past 50 years in China,

132 DA may pose a threat to the effectiveness of schistosomiasis control programs.

133 's intermediate hosts may enhance drug-based schistosomiasis control.

134 o make significant headway towards sustained schistosomiasis control.

135 group and discusses the future prospects for schistosomiasis control.

136 Schistosomiasis currently affects 240 million people wor

137 he development of an effective tool for both schistosomiasis diagnosis and drug delivery.

138 We have previously shown that schistosomiasis during pregnancy upregulates proinflamma

139 cipants (35%) were considered to have active schistosomiasis, either due to the detection of parasite

140 Schistosomiasis elicits cross-regulatory immune response

141 With the recent resolution on schistosomiasis elimination by the 65th World Health Ass

142 l diagnostic tools should be incorporated in schistosomiasis elimination programs.

143 erviced by six municipal health centres in a schistosomiasis endemic region of northeastern Leyte, Ph

144 scheme, 822 individuals were enrolled from a schistosomiasis-endemic area in Conde, Bahia, in Brazil.

145 space-time allocation of control measures in schistosomiasis-endemic contexts are discussed.

146 rried out on 693 school-aged children from 5 schistosomiasis-endemic villages in Northern Samar, the

147 The pathophysiology of female genital schistosomiasis (FGS) is only partially understood.

148 Schistosoma mansoni that causes the form of schistosomiasis found in the Western Hemisphere requires

149 ently, Uganda's crater lakes were considered schistosomiasis free due to their high-altitude location

150 h infrequent mass drug treatment, eliminates schistosomiasis from high-transmission sites.

151 09 to March 2010, the 50 patients with acute schistosomiasis (group 1) bathed in a swimming pool supp

152 tted helminths with or without deworming for schistosomiasis had little effect.

153 Schistosomiasis haematobia also appears to negatively in

154 We evaluate the evidence that early schistosomiasis has adverse effects on birth, growth, an

155 omiasis coinfections are common, and chronic schistosomiasis has been implicated in affecting the sev

156 Therefore, preventing schistosomiasis has the potential to reduce HIV transmis

157 time that patients from an outbreak of acute schistosomiasis have been compared to controls.

158 Control strategies to reduce human schistosomiasis have evolved from 'snail picking' campai

159 Here we demonstrate that during experimental schistosomiasis, hemozoin accumulating in the mouse live

160 nal diagnostic tests utilized for urogenital schistosomiasis, highlighting new insights and recent ad

161 ciated with the development of resistance to schistosomiasis, highlighting the potential importance o

162 and various infectious disorders, including schistosomiasis, HIV, and rheumatic heart disease.

163 Schistosomiasis, however, continues to spread to new geo

164 markers for evaluation of liver pathology in schistosomiasis; however, validation remains to be explo

165 r IL-4/IL-13 responsive cell lineages during schistosomiasis: IL-4Ralpha-mediated signaling in non-BM

166 In murine schistosomiasis, immunopathology and cytokine production

167 The occurrence of schistosomiasis in African infants and preschool childre

168 Schistosoma haematobium and the incidence of schistosomiasis in areas where it is currently endemic,

169 o investigate the epidemiology of urogenital schistosomiasis in Corsica, aiming to elucidate the orig

170 ars to be the case with increased urogenital schistosomiasis in humans around Lake Malawi over recent

171 iduals may provide a new tool for diagnosing schistosomiasis in patients with a low parasite burden.

172 Mozambique had the highest prevalence of schistosomiasis in school-aged children (52.8%, 95% CrI

173 s resident in an area moderately endemic for schistosomiasis in the Philippines.

174 or expanding public health interventions for schistosomiasis in women of reproductive age and prescho

175 ition of the burden and potential effects of schistosomiasis in women of reproductive age and young c

176 pem et al. and Odogwu et al. have shown that schistosomiasis in younger children is much more common

177 In another model of high-pathology schistosomiasis induced in C57BL/6 mice by immunization

178 The mechanisms underlying schistosomiasis-induced pulmonary hypertension (PH), one

179 m, and confirming it as the target of IgE in schistosomiasis infected humans.

180 n, one group was given praziquantel to treat schistosomiasis infection.

181 Urogenital schistosomiasis, infection with Schistosoma haematobium,

182 argeting MTA1 to reduce the global burden of schistosomiasis, inflammation, and neoplasia.

183 Schistosomiasis is a chronic parasitic disease affecting

184 Schistosomiasis is a debilitating neglected tropical dis

185 Schistosomiasis is a debilitating tropical disease cause

186 Schistosomiasis is a major cause of pulmonary arterial h

187 Schistosomiasis is a major neglected parasitic disease t

188 Schistosomiasis is a major parasitic disease caused by b

189 Urogenital schistosomiasis is a major public health problem in sub-

190 Schistosomiasis is a neglected tropical disease that aff

191 Schistosomiasis is a parasitic infection that is widespr

192 Bladder schistosomiasis is a prevalent disease in the developing

193 Schistosomiasis is a severe and chronic disease caused b

194 Schistosomiasis is a snail-borne parasitic disease endem

195 Acute schistosomiasis is a systemic hypersensitivity reaction

196 Schistosomiasis is among the most prevalent human parasi

197 Age prevalence curves for areas in which schistosomiasis is endemic suggest that humans develop p

198 the context of humans living in areas where schistosomiasis is endemic.

199 cted cohort in Leyte, the Philippines, where schistosomiasis is endemic.

200 soni infections, the pathology of urogenital schistosomiasis is related mainly to the egg stage, whic

201 The global burden of schistosomiasis is significant, with fibrosis a major as

202 ne in Th2 cell responsiveness during chronic schistosomiasis is the net result of the upregulation of

203 Schistosomiasis is treated with the drug praziquantel (P

204 Travel-related schistosomiasis is usually associated with prolonged fre

205 d Health Assembly's stated goal to eliminate schistosomiasis, it is time to give snail control anothe

206 In murine schistosomiasis, it was found that IL-12 and IL-23 drive

207 sin as a leading vaccine candidate for human schistosomiasis japonica and underscore the importance o

208 onitor the progression of liver pathology in schistosomiasis japonica endemic areas is lacking.

209 Schistosomiasis japonica remains a major public health a

210 . japonicum causes hepatointestinal disease (schistosomiasis japonica) and is challenging to control

211 s could represent an obstacle to eliminating schistosomiasis japonica.

212 ting the mitochondrial gene nad1 to diagnose schistosomiasis japonica.

213 nes, including those for hookworm infection, schistosomiasis, leishmaniasis, and Chagas disease, is b

214 ch drive the Th2 responses characteristic of schistosomiasis lung pathology.

215 opulation associated with protection against schistosomiasis, making hemozoin well placed to play an

216 Schistosomiasis, malaria, leishmaniasis, Chagas disease,

217 rgeted to the main human parasitic diseases (schistosomiasis, malaria, trypanosomiasis, leishmaniasis

218 D in distinct or concomitant chronic HCV and schistosomiasis mansoni infections.

219 divided into group-I: patients with chronic schistosomiasis mansoni, group-II: HCV patients without

220 In schistosomiasis mansoni, parasite eggs cause hepatointes

221 For schistosomiasis, mass deworming might be effective for w

222 By promoting endotoxemia, schistosomiasis may exert additional, maladaptive influe

223 iew of the processes associated with hepatic schistosomiasis may provide new insights into improved t

224 ted to tuberculosis, HBV, Strongyloides, and schistosomiasis, may improve outcomes.

225 sicians did not consider that an epidemic of schistosomiasis might emerge in a nonendemic area.

226 Mass deworming for schistosomiasis might slightly increase weight (0.41 kg,

227 ail populations are critically important for schistosomiasis modeling and control.

228 4B-12B) of the most well-known drug against schistosomiasis, namely praziquantel (PZQ), are reported

229 than 90% of global cases of human intestinal schistosomiasis occur.

230 f 2013, an unexpected outbreak of urogenital schistosomiasis occurred in Corsica, with more than 120

231 We propose that in chronic schistosomiasis, older individuals have repeatedly exper

232 Refined estimates of the impact of schistosomiasis on quality of life suggest that it rival

233 pio anubis) to analyze the effect of chronic schistosomiasis on severe malaria.

234 To evaluate the impact of schistosomiasis on trophoblasts of the human placenta, w

235 lmonary arterial hypertension resulting from schistosomiasis, one of the most common causes of pulmon

236 Schistosomiasis, one of the most important neglected tro

237 lidated in the context of drug screening for schistosomiasis, one of the most important NTDs.

238 ted helminths (with or without deworming for schistosomiasis or co-interventions) on growth, educatio

239 of antifibrotic reagents being developed for schistosomiasis or other fibrotic diseases associated wi

240 Schistosomiasis or snail fever is an endemic parasitic i

241 HO guidelines recommend annual treatment for schistosomiasis or soil-transmitted helminthiasis when p

242 More than 1.5 billion people are affected by schistosomiasis or soil-transmitted helminthiasis.

243 he causative agent of the intestinal form of schistosomiasis (or bilharzia).

244 Human schistosomiasis--or bilharzia--is a parasitic disease ca

245 rmore our results show the potential risk of schistosomiasis outbreaks in other European areas, warra

246 nificantly associated with the occurrence of schistosomiasis (P = .0004 for -986G>A; P = .0001 for -4

247 as observed to be a susceptibility factor in schistosomiasis (P = .03).

248 w tool for the diagnosis and surveillance of schistosomiasis, particularly in low-prevalence and low-

249 In hepatic schistosomiasis, pathology arises when schistosome eggs

250 mice that naturally display a severe form of schistosomiasis, preinfection with H. polygyrus resulted

251 idemiological data of HIV and female genital schistosomiasis prevalence and coinfection in rural Zimb

252 tematic review to identify surveys including schistosomiasis prevalence data in sub-Saharan Africa vi

253 es the observed spatial patterns of regional schistosomiasis prevalence throughout the country, provi

254 d from a reduction in infected snails, human schistosomiasis prevalence was 18 +/- 5% lower and egg b

255 the role of genetic susceptibility in murine schistosomiasis, quantitative trait loci analysis was pe

256 stosoma mansoni, the blood fluke that causes schistosomiasis, ranked among the most prevalent parasit

257 Despite effective chemotherapy, schistosomiasis remains a major public health problem in

258 Schistosomiasis remains a public health concern in devel

259 Schistosomiasis remains a serious public health issue in

260 Contrary to what we expected, acute schistosomiasis resulted in greater liver injury and mor

261 Our data indicate that maternal schistosomiasis results in a proinflammatory signature t

262 Maternal schistosomiasis results in upregulation of fibrosis-asso

263 of the national prevalences of malaria, HIV, schistosomiasis, sanitation, and water-quality indicator

264 Urogenital schistosomiasis, Schistosoma haematobium worm infection,

265 f the three major human pathogens that cause schistosomiasis, Schistosoma japonicum is the only one t

266 Approximately 200,000,000 people have schistosomiasis (schistosome infection).

267 target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and tra

268 or soil-transmitted helminthiasis (STH)- and schistosomiasis-specific WASH considerations, and a traf

269 sponsible for the neglected tropical disease schistosomiasis that affects 210 million people in 76 co

270 ades of multifaceted control efforts against schistosomiasis, the indirectly transmitted helminth Sch

271 the significant global impact of urogenital schistosomiasis, the mechanisms of bladder granulomogene

272 to transition from control to elimination of schistosomiasis, the need for updated, more sensitive di

273 ss tissue-damaging inflammation during acute schistosomiasis through an IDO-dependent mechanism.

274 y campaigns, just as many people suffer from schistosomiasis today as they did 50 years ago.

275 Schistosomiasis traditionally has been diagnosed by dete

276 k for evaluating the likelihood of sustained schistosomiasis transmission and suggest an approach to

277 f Oncomelania snail density for interrupting schistosomiasis transmission based on the longitudinal d

278 of Oncomelania snail density below which the schistosomiasis transmission cannot be sustained were 0.

279 ents the first application of an integrative schistosomiasis transmission model at a whole-country sc

280 iscoveries in the pathogenesis of urogenital schistosomiasis (UGS): (1) comparative genomics, (2) the

281 The capability to diagnose cases of human schistosomiasis using noninvasively collected clinical s

282 In 2016, Science ranked the schistosomiasis vaccine as one of the top 10 vaccines th

283 alpain, is a leading antigen candidate for a schistosomiasis vaccine.

284 ion article, we focus on salient features of schistosomiasis vaccines in different phases of the clin

285 e models adjusted for geohelminths, maternal schistosomiasis was associated with increased levels of

286 Annual preventive chemotherapy against schistosomiasis was highly cost-effective in treatment o

287 Bladder schistosomiasis was suspected after contrast-enhanced co

288 ical consequence of wound healing in chronic schistosomiasis, was exacerbated in Batf3(-/-) mice infe

289 With a focus on children with schistosomiasis, we assess the risk for increased HIV tr

290 lacental compartments in pregnant women with schistosomiasis were 1.3- and 2.4-fold higher, respectiv

291 animals (mice and rabbits) or patients with schistosomiasis were measured by ELISA.

292 responses were revealed during experimental schistosomiasis where, even in the face of robust Th2 ge

293 ed to be a risk factor for susceptibility to schistosomiasis, whereas the homozygous genotypes of maj

294 istosomes are parasitic flatworms that cause schistosomiasis, which affects hundreds of millions of p

295 Treatment for schistosomiasis, which is responsible for more than 280,

296 ined the first tractable model of urogenital schistosomiasis with an established mouse model of bacte

297 We combined a mouse model of urogenital schistosomiasis with macrophage-depleting liposomal clod

298 cellular and molecular mechanisms of hepatic schistosomiasis, with an emphasis on the major cellular

299 The occurrence of schistosomiasis within African infants and preschool chi

300 Mouse models demonstrate that schistosomiasis worsens a malaria infection; however, ju